Lead
Boston Scientific has invested $1.5 billion to secure a 34% equity stake in MiRus, a company developing a balloon-expandable transcatheter aortic valve replacement system. The agreement, announced on May 18, 2026, also grants Boston Scientific an exclusive option to acquire the MiRus TAVR system for additional payments totaling $3 billion.
Details
The deal provides Boston Scientific with an exclusive option to acquire the MiRus TAVR system, contingent upon the completion of certain clinical and regulatory milestones. This strategic investment follows Boston Scientific’s previous decision to cease sales of its Acurate Neo2 and Acurate Prime TAVR devices.
Company Background
Boston Scientific, based in Marlborough, Massachusetts, is a leading innovator in medical devices, with a focus on less invasive procedures to improve patient outcomes. MiRus, on the other hand, is known for its development in the TAVR space, aiming to offer advanced solutions for aortic valve diseases.
Market Context
This acquisition is significant as it marks Boston Scientific’s renewed effort to establish a presence in the growing TAVR market, following the setback of their previous TAVR platform. The move underscores the competitive dynamics in the medical device industry and the strategic importance of innovation and market re-entry in high-growth sectors.
If you are exploring product design and medical device engineering, BangDesign has relevant experience.
Source: MedTech Dive